المؤلفون: Katsimpris, Andreas, Antoniadis, Antonios G., Dessypris, Nick, Karampinos, Konstantinos, Gogas, Helen J., Petridou, Eleni T.

المصدر: Oncology Research and Treatment ; volume 47, issue 5, page 206-217 ; ISSN 2296-5270 2296-5262

الإتاحة: https://doi.org/10.1159/000538278Test
https://karger.com/ort/article-pdf/47/5/206/4224253/000538278.pdfTest

المؤلفون: Dummer, Reinhard, Flaherty, Keith T, Robert, Caroline, Arance, Ana, B de Groot, Jan Willem, Garbe, Claus, Gogas, Helen J, Gutzmer, Ralf, Krajsová, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandalà, Mario, Schadendorf, Dirk, Yamazaki, Naoya, Pietro, Alessandra di, Cantey-Kiser, Jean, Edwards, Michelle, Ascierto, Paolo A

المصدر: Future Oncology ; volume 19, issue 16, page 1091-1098 ; ISSN 1479-6694 1744-8301

الإتاحة: https://doi.org/10.2217/fon-2022-1258Test

المؤلفون: Ascierto, Paolo A, Dummer, Reinhard, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Robert, Caroline, Flaherty, Keith T

المصدر: Ascierto, Paolo A; Dummer, Reinhard; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Robert, Caroline; Flaherty, Keith T (2023). Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of Clinical Oncology, 41(29):4621-4631.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health, Cancer Research, Oncology

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/238964/7/ZORA238964.pdfTest; info:pmid/37506329; urn:issn:0732-183X

الإتاحة: https://doi.org/10.5167/uzh-23896410.1200/jco.22.02322Test
https://www.zora.uzh.ch/id/eprint/238964Test/
https://www.zora.uzh.ch/id/eprint/238964/7/ZORA238964.pdfTest

المؤلفون: Ascierto, Paolo A, Dummer, Reinhard, Gogas, Helen J, Flaherty, Keith T, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, de Groot, Jan Willem B, Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D, Robert, Caroline

المصدر: Ascierto, Paolo A; Dummer, Reinhard; Gogas, Helen J; Flaherty, Keith T; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; de Groot, Jan Willem B; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D; Robert, Caroline (2020). Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. European Journal of Cancer, 126:33-44.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/183844/8/1-s2.0-S095980491930841X-main.pdfTest; info:pmid/31901705; urn:issn:0959-8049

الإتاحة: https://doi.org/10.5167/uzh-18384410.1016Test/j.ejca.2019.11.016
https://www.zora.uzh.ch/id/eprint/183844Test/
https://www.zora.uzh.ch/id/eprint/183844/8/1-s2.0-S095980491930841X-main.pdfTest

المؤلفون: Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen J., Flaherty, Keith T., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, de Groot, Jan Willem B., Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D., Robert, Caroline

المساهمون: Pfizer, Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Amgen, Pierre Fabre, Amicus, Boehringer-Ingelheim, NeraCare, Philogen, Sanofi, Neracare, Array BioPharma, Boehringer Ingelheim, LEO Pharma, Hexal, InflaRx, Helsinn, GI Innovation, Immunocore, Incyte, Regeneron, 4SC, AstraZeneca, Merck-EMD, Ultimovacs, Sun Pharma, Johnson&Johnson, Merck Serono, Servier, Biontech

المصدر: European Journal of Cancer ; volume 126, page 33-44 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016Test/j.ejca.2019.11.016
https://api.elsevier.com/content/article/PII:S095980491930841X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S095980491930841X?httpAccept=text/plainTest

المؤلفون: Gogas, Helen J, Flaherty, Keith T, Dummer, Reinhard, Ascierto, Paolo A, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Sileni, Vanna Chiarion, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D, Robert, Caroline

المصدر: Gogas, Helen J; Flaherty, Keith T; Dummer, Reinhard; Ascierto, Paolo A; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Sileni, Vanna Chiarion; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D; Robert, Caroline (2019). Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European Journal of Cancer, 119:97-106.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/174049/1/809_Gogas_H._et_al._Adverse_events_associated_with_encorafenib_plus_binimetinib_in_the_COLUMBUS_study_EJC_2019.pdfTest; info:pmid/31437754; urn:issn:0959-8049

الإتاحة: https://doi.org/10.5167/uzh-17404910.1016Test/j.ejca.2019.07.016
https://www.zora.uzh.ch/id/eprint/174049Test/
https://www.zora.uzh.ch/id/eprint/174049/1/809_Gogas_H._et_al._Adverse_events_associated_with_encorafenib_plus_binimetinib_in_the_COLUMBUS_study_EJC_2019.pdfTest

المؤلفون: Gogas, Helen J., Flaherty, Keith T., Dummer, Reinhard, Ascierto, Paolo A., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Sileni, Vanna Chiarion, Dutriaux, Caroline, de Groot, Jan Willem B., Yamazaki, Naoya, Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D., Robert, Caroline

المساهمون: Array BioPharma, Inc., Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Amgen, Pierre Fabre, BMS, Genentech, Array, MSD, Merck, Amicus, Boehringer-Ingelheim, Boehringer Ingelheim, LEO Pharma, Incyte, Regeneron, 4SC, AstraZeneca, EMD, Pfizer, Philogen, Array BioPharma, Johnson & Johnson, MerckSerono, Almirall-Hermal, Merck-Serono, Pierre-Fabre, SUN, Roche Pharma, Takeda, Servier, Ono Pharmaceutical

المصدر: European Journal of Cancer ; volume 119, page 97-106 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016Test/j.ejca.2019.07.016
https://api.elsevier.com/content/article/PII:S0959804919304241?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0959804919304241?httpAccept=text/plainTest

المؤلفون: Dummer, Reinhard, Flaherty, Keith T, Robert, Caroline, Arance, Ana, B de Groot, Jan Willem, Garbe, Claus, Gogas, Helen J, Gutzmer, Ralf, Krajsová, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandalà, Mario, Schadendorf, Dirk, Yamazaki, Naoya, Pietro, Alessandra di, Cantey-Kiser, Jean, Edwards, Michelle, Ascierto, Paolo A

مصطلحات موضوعية: Medizin

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=unidue___bib::65e7bf1be4294e8c2e2936e256ca66eaTest
https://www.ncbi.nlm.nih.gov/pubmed/37309702Test

المؤلفون: Dummer, Reinhard, Ascierto, Paolo A, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Moutouh-de Parseval, Laure A, Pickard, Michael D, Sandor, Victor, Robert, Caroline, Flaherty, Keith T

المصدر: Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A; Pickard, Michael D; Sandor, Victor; Robert, Caroline; Flaherty, Keith T (2018). Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 19(5):603-615.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/151962/1/747_Dummer_R._et_al._Encorafenib_plus_binimetinib_versus_vemurafenib_or_encorafenib_in_patients_Lancet_Oncology_2018.pdfTest; https://www.zora.uzh.ch/id/eprint/151962/8/Dummer_et_al_Lancet_Oncology_13.12.17.pdfTest; info:pmid/29573941; urn:issn:1470-2045

الإتاحة: https://doi.org/10.5167/uzh-15196210.1016/S1470-2045Test(18)30142-6
https://www.zora.uzh.ch/id/eprint/151962Test/
https://www.zora.uzh.ch/id/eprint/151962/1/747_Dummer_R._et_al._Encorafenib_plus_binimetinib_versus_vemurafenib_or_encorafenib_in_patients_Lancet_Oncology_2018.pdfTest
https://www.zora.uzh.ch/id/eprint/151962/8/Dummer_et_al_Lancet_Oncology_13.12.17.pdfTest

المؤلفون: Long, Georgina V., Stephen Hodi, F., Lipson, Evan J., Schadendorf, Dirk, Ascierto, Paolo A., Matamala, Luis, Salman, Pamela, Castillo Gutiérrez, Erika, Rutkowski, Piotr, Gogas, Helen J., Lao, Christopher D., Janoski De Menezes, Juliana, Dalle, Stéphane, Arance, Ana, Grob, Jean-Jacques, Keidel, Sarah, Shaikh, Anadil, Sobiesk, Anne Marie, Dolfi, Sonia, Tawbi, Hussein A.

المصدر: NEJM Evidence; Apr2023, Vol. 2 Issue 4, p1-10, 10p

مصطلحات موضوعية: COMBINATION drug therapy, CONFIDENCE intervals, MELANOMA, TREATMENT effectiveness, RANDOMIZED controlled trials, NIVOLUMAB, DESCRIPTIVE statistics, PROGRESSION-free survival, STATISTICAL sampling, DRUG side effects, GENETIC techniques, OVERALL survival, DOSAGE forms of drugs